Haemonetics Co. (NYSE:HAE) Shares Acquired by ProShare Advisors LLC

Posted by on Apr 27th, 2023

ProShare Advisors LLC increased its position in Haemonetics Co. (NYSE:HAE – Get Rating) by 13.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 10,419 shares of the medical instruments supplier’s stock after purchasing an additional 1,200 shares during the period. ProShare Advisors LLC’s holdings in Haemonetics were worth $819,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in HAE. Bank of Montreal Can increased its stake in Haemonetics by 5.1% in the fourth quarter. Bank of Montreal Can now owns 14,820 shares of the medical instruments supplier’s stock valued at $1,186,000 after purchasing an additional 720 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Haemonetics by 7.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,988 shares of the medical instruments supplier’s stock worth $550,000 after acquiring an additional 485 shares during the period. Legato Capital Management LLC acquired a new stake in Haemonetics during the 4th quarter worth approximately $249,000. New York State Common Retirement Fund grew its stake in shares of Haemonetics by 2.5% in the 4th quarter. New York State Common Retirement Fund now owns 51,493 shares of the medical instruments supplier’s stock valued at $4,050,000 after purchasing an additional 1,274 shares during the last quarter. Finally, Versor Investments LP increased its holdings in shares of Haemonetics by 152.7% in the fourth quarter. Versor Investments LP now owns 11,600 shares of the medical instruments supplier’s stock valued at $912,000 after purchasing an additional 7,009 shares during the period.

Analyst Ratings Changes

HAE has been the topic of several analyst reports. Citigroup lowered their target price on shares of Haemonetics from $95.00 to $90.00 in a report on Monday, April 3rd. Mizuho lifted their price target on shares of Haemonetics from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, February 8th. Barrington Research lifted their price objective on Haemonetics from $94.00 to $103.00 and gave the stock an “outperform” rating in a report on Wednesday, February 8th. Morgan Stanley lifted their price target on Haemonetics from $84.00 to $88.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 8th. Finally, StockNews.com assumed coverage on shares of Haemonetics in a research note on Thursday, March 16th. They set a “buy” rating for the company. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and a consensus target price of $100.17.

Haemonetics Trading Down 1.0 %

NYSE HAE opened at $82.33 on Thursday. The company has a 50-day moving average of $80.55 and a 200-day moving average of $81.26. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.11 and a quick ratio of 1.99. Haemonetics Co. has a 12 month low of $48.67 and a 12 month high of $91.39. The company has a market cap of $4.15 billion, a P/E ratio of 44.50, a P/E/G ratio of 2.58 and a beta of 0.44.

Haemonetics (NYSE:HAE – Get Rating) last announced its quarterly earnings data on Tuesday, February 7th. The medical instruments supplier reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.06. Haemonetics had a net margin of 8.48% and a return on equity of 19.84%. The company had revenue of $305.30 million during the quarter, compared to analysts’ expectations of $300.47 million. During the same period in the previous year, the company earned $0.84 EPS. The business’s quarterly revenue was up 17.5% compared to the same quarter last year. As a group, equities analysts predict that Haemonetics Co. will post 2.94 earnings per share for the current year.

Haemonetics Company Profile

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.

Featured Stories

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.